These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 25914925)

  • 1. Significant reduction of aggression with guanfacine extended release in an adolescent with Prader-Willi syndrome.
    Singh D; Kadakia N; Pinkhasov A
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):376-7. PubMed ID: 25914925
    [No Abstract]   [Full Text] [Related]  

  • 2. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study.
    Singh D; Wakimoto Y; Filangieri C; Pinkhasov A; Angulo M
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):313-317. PubMed ID: 30724590
    [No Abstract]   [Full Text] [Related]  

  • 3. Guanfacine extended-release (intuniv) for ADHD.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
    Sallee FR; Eaton K
    Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of excessive weight gain with guanfacine extended release: 9.53 kg in 4 weeks.
    Khan MA; Jain G; Soltys SM; Takahashi A
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):256-7. PubMed ID: 22537187
    [No Abstract]   [Full Text] [Related]  

  • 6. Guanfacine extended release in two patients with pervasive developmental disorders.
    Blankenship K; Erickson CA; Stigler KA; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):287-90. PubMed ID: 21663433
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
    Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ;
    Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged bradycardia and hypotension following guanfacine extended release overdose.
    Walton J; Byrum M; Shumaker A; Coury DL
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):463-5. PubMed ID: 25010857
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
    Verplaetse TL; Roberts W; Moore KE; Peltier MR; Oberleitner LM; McKee SA
    J Clin Psychopharmacol; 2019; 39(2):124-128. PubMed ID: 30707118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended-release tablets.
    Inoue Y; Morita H; Nozawa K; Kanazu T
    Biopharm Drug Dispos; 2019 Sep; 40(8):282-293. PubMed ID: 31313320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole in the Treatment of Obsessive Compulsive Disorder and Aggressive Behaviors in a Child With Prader Willi Syndrome: A Case Report.
    Akça ÖF; Yilmaz S
    J Clin Psychopharmacol; 2016 Oct; 36(5):526-8. PubMed ID: 27518476
    [No Abstract]   [Full Text] [Related]  

  • 15. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacology of the Rage Attack Phenomenon in a Child with Obsessive Compulsive Disorder.
    Weiss-Goldman N; Arditi B; Rice T; Coffey BJ
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):360-362. PubMed ID: 29889566
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F; Connor DF; Newcorn JH
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing disruptive behaviour in autism-spectrum disorder with guanfacine.
    Propper L
    J Psychiatry Neurosci; 2018 Aug; 43(5):359-360. PubMed ID: 30125242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.